A Real Case Study: The 2026 PCAC Peptide Review

Regulatory Landscape·Lesson 3 of 4·Beginner·8 min read

A Real Case Study: The 2026 PCAC Peptide Review

What actually happened when FDA’s advisory committee reviewed BPC-157 and six other peptides for the 503A Bulks List.

Research use only. This lesson summarizes public regulatory proceedings as reported at the time of writing. It is not legal advice, and regulatory status can change — verify current status directly with FDA.gov before drawing any conclusions. This is not medical advice or an instruction for human or veterinary use.
📌

How BPC-157 Ended Up in Category 2

In 2023, FDA placed BPC-157 into Category 2 of the interim 503A bulks list, reflecting safety concerns the agency identified — among the issues cited were limited human clinical data and questions around impurities and immunogenicity. Category 2 status meant FDA would consider enforcement action against compounding pharmacies using BPC-157, and remains the compound’s formal status as of this writing.

What Happened at the July 2026 PCAC Meeting

  • The meeting: FDA’s Pharmacy Compounding Advisory Committee met July 23–24, 2026 to review seven peptide bulk substances for potential inclusion on the 503A Bulks List
  • The compounds reviewed: BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and DSIP (emideltide) — all but DSIP are covered in the Signal Library
  • The vote: the committee recommended six of the seven for potential inclusion; BPC-157 specifically passed 8–6 with one abstention. DSIP was the one rejected
  • The notable wrinkle: the committee’s recommendation went against FDA’s own scientific staff, who had recommended against all seven
⚠️

What This Vote Did and Didn’t Do

A PCAC recommendation is exactly that — a recommendation, not a rule change. FDA still has to decide whether to act on it, and doing so requires a formal rulemaking process that, realistically, extends into 2027. As of the vote, the regulatory status of these substances hadn’t changed: BPC-157 remained in Category 2 despite the favorable committee vote. This is a useful real-world illustration of a distinction worth remembering — an advisory committee’s opinion and a binding agency action are two different things, even when the committee overrules the agency’s own staff.

“A favorable advisory vote is a signal about where things might be headed — it is not, by itself, a change in what’s actually allowed.”

✅ Quick Recap

  • BPC-157 was placed in Category 2 of FDA’s interim 503A bulks list in 2023 over identified safety concerns
  • In July 2026, PCAC reviewed seven peptides and recommended six — including BPC-157 — for potential 503A bulks list inclusion, rejecting DSIP
  • The committee’s recommendation went against FDA’s own scientific staff’s assessment
  • A PCAC recommendation is non-binding; formal FDA rulemaking is a separate, ongoing process

Next: Why Regulatory Status Isn’t Permanent →

← Back to Regulatory Landscape